2016指南变迁解读课件.pptxVIP

2016 NCCN Guidelines;NCCN AML 2016 V1;目录;AML-1 / EVALUATION FOR ACUTE LEUKEMIA;AML-2 / APL CLASSIFICATION;AML-3 / TREATMENT INDUCTION (HIGH RISK);AML-6 / APL-THERAPY FOR RELAPSE;AML-7/ AML CLASSIFICATION;AML-8 / AML POST-INDUCTION THERAPY AFTER STANDARD-DOSE CYTARABINE, 60y;AML-9 / AML POST-INDUCTION THERAPY AFTER HIGH-DOSE CYTARABINE, 60y;AML-10 / POST-REMISSION THERAPY, 60y;AML-11 / AML ≥ 60y;AML-12 / AML POST-INDUCTION THERAPY AFTER STANDARD-DOSE CYTARABINE, ≥ 60y;AML-13 / POST-REMISSION THERAPY, ≥ 60y ;AML-14 / SURVEILLANCE (AFTER COMPLETION OF CONSOLIDATION);AML-A / RISK STATUS EVALUATIO